precision cardiology market
The global precision cardiology market is projected to reach $3,584.6 million by 2031, reveals the premium market intelligence study by Our Research Team. The study also highlights that the market is set to witness a CAGR of 12.90% during the period between 2021 and 2031.
The comprehensive study of the global precision cardiology market by Our Research Team extensively covers the following:
• Market numbers on micro-segments that are influencing the market
• More than 200 products and services present in the market
• Over 20 brands were evaluated
• Market share analysis for more than 15 product categories
• End-user preference data for over 20 end users
• Detailed global and regional market share analysis including the scrutiny of more than 17 countries
• Study of data of more than 17 companies
Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 200+ products and services.
Our Research Team study indicates that the rising burden of cardiovascular diseases, increasing focus on early cardiovascular disease screening, and decreasing cost of sequencing, among others, are fueling the growth of the global precision cardiology market.
The market intelligence by Our Research Team additionally throws a spotlight on the opportunities existing in the market, such as massive scope for adoption of next-generation sequencing (NGS)-based cardiology tests in emerging markets.
To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include offering, sample, technology, application, end users, and regions. The offering and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analysis of preferred precision cardiology products and services. Pertaining to the market segmentation, the offering segment is segmented into products and services. Also, the sample segment of the market has been broadly segmented into blood and non-blood-based samples. In addition, the technology segment of the market has been segmented in sequencing (next-generation sequencing and Sanger sequencing), polymerase chain reaction, microarray and other technologies. Further, the application segment of the market has been segmented into cardiomyopathy, arrhythmia, aortopathy and vascular diseases, familial hypercholesterolemia (FH), congenital heart defects and syndromes, and other applications. Finally, the end user segment of the market has been segmented into hospitals and diagnostic laboratories, academic and research institutes, and other end users.
Key insights are drawn from in-depth interviews with the key opinion leaders of more than 17 leading companies, market participants, and vendors. The key players profiled in the report include ARUP Laboratories, CENTOGENE N.V., Eurofins Scientific, Exact Sciences Corporation, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, OPKO Health, Inc., OraSure Technologies, Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Sema4 OpCo, Inc., and Thermo Fisher Scientific Inc.
The study also offers strategic recommendations that can help organizations in tracking various precision cardiology tests that are changing the dynamics of the market. The recommendations by Our Research Team also offer bespoke research services to help organizations meet their objectives.
Who should buy this report?
• Cardiovascular genetic test developers and providers who are involved in the development and commercialization of their respect offerings.
• Emerging companies in the field of precision cardiology to assess the market situation.
How can market intelligence on Precision Cardiology add value to an organization’s decision-making process?
• Aid in precision cardiology test development
• Help in targeting a segment for launching new tests
• Offer go to market access strategies
• Support in diversifying the portfolio basis risk and progression of underlying technologies
• Help in analyzing specifications
• Aid in understanding the end-user landscape
• Gain holistic views pertaining to the regions and understand the market potential of the countries.
• Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companies
Insightful Questions Covered to Enable Companies take Strategic Decisions.
• How is precision cardiology revolutionizing the field of cardiovascular care?
• What are the major market drivers, challenges, and opportunities in the global precision cardiology market?
• What are the underlying structures resulting in the emerging trends within the global precision cardiology market?
• How did the COVID-19 pandemic impact the global precision cardiology ecosystem?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of precision cardiology products and services?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Offering (product and service)
o Sample (blood and non-blood)
o Technology (sequencing, polymerase chain reaction, microarray, and other technologies)
o Application (cardiomyopathy, arrhythmia, aortopathy and vascular diseases, familial hypercholesterolemia, congenital heart defects and syndromes, and other applications)
o End user (hospitals and diagnostic laboratories, academic and research institutes, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global precision cardiology market?
• Which companies are anticipated to be highly disruptive in the future, and why?